Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/01/2022* -- Results Q3 2022 -- -0.23 --
11/01/2022* -- Earnings Call Q3 2022 -- -- --
08/02/2022 -- Results Q2 2022 -0.26 -0.21 -23.81%
08/02/2022 16:30 EST Earnings Call Q2 2022 -- -- --
05/03/2022 -- Results Q1 2022 -0.21 -0.21 0.00%
05/03/2022 16:30 EST Earnings Call Q1 2022 -- -- --
02/22/2022 -- Results Q4 2021 -0.27 -0.18 -46.74%
02/22/2022 16:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/01/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/02/2022
Beat/Miss Upgrade
Return Since -4.84%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Apollo Endosurgery Inc is active in the healthcare sector based in the United States. As a developer of medical devices, Apollo focuses on addressing obesity, as well as other gastrointestinal disorders. Its products are used by general surgeons, bariatric surgeons and gastroenterologists in a variety of settings to provide interventional therapy to patients who suffer from obesity. The company's products include the OverStitch Endoscopic Suturing System, X-Tack Endoscopic HeliX Tacking System, and the Orbera Intragastric Balloon System.
URL https://www.apolloendo.com
Investor Relations URL https://ir.apolloendo.com/
HQ State/Province Texas
Sector Healthcare
Industry Medical Devices
Equity Style Small Cap/Growth
Next Earnings Release Nov. 01, 2022 (est.)
Last Earnings Release Aug. 02, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-91.95%
-30.46%
-53.95%
-38.39%
-17.39%
19.30%
147.9%
-34.64%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-23.87%
--
--
--
--
--
--
--
-51.69%
-35.79%
-38.13%
-31.16%
-24.87%
108.1%
-27.93%
-13.82%
-40.72%
-7.59%
-78.57%
4.09%
-76.55%
-0.62%
-24.70%
-53.18%
28.54%
-14.78%
-47.58%
48.46%
17.10%
-95.00%
-57.48%
77.60%
-59.57%
As of September 30, 2022.

Profile

Edit
Apollo Endosurgery Inc is active in the healthcare sector based in the United States. As a developer of medical devices, Apollo focuses on addressing obesity, as well as other gastrointestinal disorders. Its products are used by general surgeons, bariatric surgeons and gastroenterologists in a variety of settings to provide interventional therapy to patients who suffer from obesity. The company's products include the OverStitch Endoscopic Suturing System, X-Tack Endoscopic HeliX Tacking System, and the Orbera Intragastric Balloon System.
URL https://www.apolloendo.com
Investor Relations URL https://ir.apolloendo.com/
HQ State/Province Texas
Sector Healthcare
Industry Medical Devices
Equity Style Small Cap/Growth
Next Earnings Release Nov. 01, 2022 (est.)
Last Earnings Release Aug. 02, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter APEN Tweets